[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349652-105":59,"doc-detail-349652-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","itpripl1-a-tumor-immune-associated-biomarker-with-prognostic-and-therapeutic-implications-in-gastrointestinal-cancer","ITPRIPL1 - A tumor immune-associated biomarker with prognostic and therapeutic implications in gastrointestinal cancer","","Inositol 1,4,5-trisphosphate receptor-interacting protein-like 1 (ITPRIPL1) is linked to tumor-immune regulation, but its tumor-type specificity and clinical relevance in gastrointestinal malignancies were unclear. An integrative multi-cohort analysis across stomach, colon, rectal, and esophageal cancers showed ITPRIPL1 upregulation, with prognostic impact highly tumor-specific: elevated expression predicted unfavorable survival in stomach adenocarcinoma. Associations with immune pathways, genomic instability, T-cell context, ZAP70 expression, and single-cell/immunofluorescence enrichment supported an immune-associated biomarker role. Higher ITPRIPL1 also correlated with improved survival in some pretreatment immunotherapy cohorts and lower IC50 values for multiple agents.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/itpripl1-a-tumor-immune-associated-biomarker-with-prognostic-and-therapeutic-implications-in-gastrointestinal-cancer/349652/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/itpripl1-a-tumor-immune-associated-biomarker-with-prognostic-and-therapeutic-implications-in-gastrointestinal-cancer/349652.png","ImageObject",300,407,{"name":92,"@type":93},"MrHarris58","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What was the main goal regarding ITPRIPL1 in gastrointestinal cancers?","Question",{"text":113,"@type":114},"To determine whether ITPRIPL1 shows tumor-type specificity and has clinical relevance for prognosis and therapy across major gastrointestinal malignancies.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does ITPRIPL1 expression relate to prognosis in different GI tumor types?",{"text":118,"@type":114},"Although ITPRIPL1 was upregulated across GI cancers, unfavorable survival prediction was consistently observed only in stomach adenocarcinoma, indicating strong tumor-specific prognostic significance.",{"name":120,"@type":111,"acceptedAnswer":121},"Which immune features are associated with ITPRIPL1 in gastric cancer?",{"text":122,"@type":114},"In gastric cancer, ITPRIPL1 aligns with immune-related pathways and immune-context dependence, particularly varying with CD8⁺/CD4⁺ T-cell abundance, alongside exploratory association for ZAP70.",{"name":124,"@type":111,"acceptedAnswer":125},"Does higher ITPRIPL1 expression relate to immunotherapy outcomes and drug sensitivity?",{"text":126,"@type":114},"Exploratory analyses linked higher ITPRIPL1 with favorable survival in selected external pretreatment immunotherapy cohorts, and it correlated with lower IC50 values for multiple agents in cancer cell-line pharmacogenomic datasets.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},349652,1790148784,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":144,"language":145,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":67,"update_tm":149,"read_time":150,"preview_page_count":19,"preview_urls":151},687212988360,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nITPRIPL1 : Atumor immuneassociated biomarker with prognostic and therapeutic implications in gastrointestinal cancer  \nYahui Lyu1,10, Hanzhang Lyu2,10, Guodong Guo3,10, Hongmei Zhao4,10, Weiteng Lin2,10, Youqing Wang1, Hong Chen3, Qi Huang5, Fangqin Xue2,3, Ning Wang6, Jinlan Lin7 & Yue Tian8,9  \nInositol 1,4,5-trisphosphate receptor-interacting protein-like 1(ITPRIPL1) has recently been implicated in tumor-immune regulation, yet its tumor-type specificity and clinical relevance in gastrointestinal malignancies remain unclear. Here, we performed an integrative analysis of ITPRIPL1 across stomach adenocarcinoma (STAD), colon adenocarcinoma (COAD), rectal adenocarcinoma (READ), and esophageal carcinoma (ESCA) using bulk transcriptomics, immune pathway analyses, survival modeling, single-cell RNA sequencing, immunofluorescence validation, and therapeutic correlation analyses. Although ITPRIPL1 was upregulated across gastrointestinal cancers, its prognostic significance was highly tumor-specific, with elevated expression consistently predicting unfavorable survival only in STAD. In gastric cancer, ITPRIPL1 expression was closely associated with immune-related pathways and genomic instability features, and its prognostic association varied across immune contexts, particularly according to CD8⁺/CD4⁺ T-cell abundance, with an exploratory association also observed for zeta-chain-associated protein kinase 70 (ZAP70) expression. Singlecell and immunofluorescence analyses demonstrated preferential enrichment of ITPRIPL1 inT  \ncells and tumor-adjacent immune structures. Notably, Exploratory analyses further showed that higher ITPRIPL1 expression was associated with favorable survival outcomes in selected external pretreatment immunotherapy cohorts and with lower IC50 values for several agents in cancer cell-line pharmacogenomic datasets. Collectively, these findings identify ITPRIPL1 as an immune-associated biomarker with primary clinical relevance in gastric cancer.  \nKeywords ITPRIPL1, Gastric cancer, Gastrointestinal tumors, Tumor immune microenvironment, Prognosis, T cell infiltration, Immunotherapy response  \nAbbreviations  \nCD4Tconv Conventional CD4⁺ T cells  \n1Department of Rheumatology and Immunology, Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou 313000, Zhejiang, China. 2Shengli Clinical Medical College of Fujian Medical University, Fuzhou 350001, Fujian, China. 3Fuzhou University Affiliated Provincial Hospital, Fuzhou University School of Medicine, Fuzhou 350001, Fujian, China. 4Department of Health Examination and management, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, Shanghai, China.  \n5Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai 200092, Shanghai, China. 6Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou 313000, Zhejiang, China. 7Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China. 8Department of Cardiovascular Surgery, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian, China. 9Key Laboratory of Cardio-Thoracic Surgery (Fujian Medical University), Fujian Province University, Fuzhou 350001, Fujian, China. 10Yahui Lyu, Hanzhang Lyu, Guodong Guo, Hongmei Zhao and Weiteng Lin contributed equally to this work. email: [fangqinx@163.com](fangqinx@163.com); [wning2425@163.com](wning2425@163.com);  \n[linjinlan@fjmu.edu.cn](linjinlan@fjmu.edu.cn); [ty19946257384@163.com](ty19946257384@163.com)  \n[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nCD8Tex Exhausted CD8⁺ T cells  \nCOAD Colon adenocarcinoma  \nCMap Connectivity Map  \nCRC Colorectal cancer  \nCTRP Cancer Therapeutics Response Portal  \nDAPI 4′,6-diamidino-2-phenylindole  \nDFI Disease-free interval  \nDSS Di","cbCaidlgZfivC4LT","https://ap.wps.com/l/cbCaidlgZfivC4LT","pdf",8018708,22,"English","# Background\n## Tumor heterogeneity and tumor microenvironment in GI cancers\n# Study Approach\n## Integrative analyses across GI cancer types\n## Multi-omics and immune pathway modeling\n# Key Findings\n## Tumor-specific prognostic value in gastric cancer\n## Links to immune context and immune cell infiltration\n## Biomarker relevance to immunotherapy and drug sensitivity\n# Conclusion\n## ITPRIPL1 as an immune-associated biomarker for gastric cancer","[{\"question\":\"What was the main goal regarding ITPRIPL1 in gastrointestinal cancers?\",\"answer\":\"To determine whether ITPRIPL1 shows tumor-type specificity and has clinical relevance for prognosis and therapy across major gastrointestinal malignancies.\"},{\"question\":\"How does ITPRIPL1 expression relate to prognosis in different GI tumor types?\",\"answer\":\"Although ITPRIPL1 was upregulated across GI cancers, unfavorable survival prediction was consistently observed only in stomach adenocarcinoma, indicating strong tumor-specific prognostic significance.\"},{\"question\":\"Which immune features are associated with ITPRIPL1 in gastric cancer?\",\"answer\":\"In gastric cancer, ITPRIPL1 aligns with immune-related pathways and immune-context dependence, particularly varying with CD8⁺/CD4⁺ T-cell abundance, alongside exploratory association for ZAP70.\"},{\"question\":\"Does higher ITPRIPL1 expression relate to immunotherapy outcomes and drug sensitivity?\",\"answer\":\"Exploratory analyses linked higher ITPRIPL1 with favorable survival in selected external pretreatment immunotherapy cohorts, and it correlated with lower IC50 values for multiple agents in cancer cell-line pharmacogenomic datasets.\"}]","ITPRIPL1 - A tumor immune-associated biomarker with prognostic and therapeutic implications in gastrointestinal cancer | PDF",1790084770,55,[152,156,160,164],{"page_no":8,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e1bf61a2ec5556bfd632ed56f3fbcb76.webp",983,1291,{"page_no":14,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/19826ecb03fd0bda47fa19f3ab6cfe00.webp",982,1290,{"page_no":81,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bfeffb100c0ea1e4950da386c49701f1.webp",981,1289,{"page_no":19,"url":165,"width":166,"height":167},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eadc23892ffc83244779a40431edd423.webp",980,1287]